Subcellular localization of 57Co bleomycin in normal and tumor tissues

A.W. Konings, J.J. Rasker

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

57Co-bleomycin appears to be one of the best tumor detecting agents at the moment. The localization within the cells is not yet known. This preclinical investigation had the aim to study the subcellular distribution of 57Co-bleomycin in liver, spleen and tumors of rats and mice. Mice with transplanted lymphosarcoma and osteosarcoma were used and rats with transplanted rhabdomyosarcoma. The concentration of 57Co-bleomycin was 2 to 10 times higher in the tumors as compared to the (normal) liver. This accumulation property was not found with the control substance: 57CoCl2. The highest radioactivity of 57Co-bleomycin (cpm/mg protein) was observed in subcellular fractions containing mitochondria and lysosomes. After treatment of these fractions with hypertonic solutions it could be shown that enzymes of the mitochondrial matrix remained inside the vesicles under conditions of almost complete release of 57Co-bleomycin. Half of the lysosomal enzyme acid phosphatase was released too. From these experiments it is concluded that 57Co-bleomycin is preferentially localized in heavy secondary lysosomes which are more fragile than the lighter lysosomes in the cells.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalStrahlentherapie
Volume154
Issue number1
Publication statusPublished - 1 Jan 1978
Externally publishedYes

Fingerprint

Bleomycin
Lysosomes
Neoplasms
Hypertonic Solutions
Subcellular Fractions
Rhabdomyosarcoma
Liver
Osteosarcoma
Enzymes
Acid Phosphatase
Non-Hodgkin's Lymphoma
Radioactivity
Mitochondria
Spleen
indium-bleomycin
Proteins

Cite this

@article{31232be242504b57b9d9130b96931cb9,
title = "Subcellular localization of 57Co bleomycin in normal and tumor tissues",
abstract = "57Co-bleomycin appears to be one of the best tumor detecting agents at the moment. The localization within the cells is not yet known. This preclinical investigation had the aim to study the subcellular distribution of 57Co-bleomycin in liver, spleen and tumors of rats and mice. Mice with transplanted lymphosarcoma and osteosarcoma were used and rats with transplanted rhabdomyosarcoma. The concentration of 57Co-bleomycin was 2 to 10 times higher in the tumors as compared to the (normal) liver. This accumulation property was not found with the control substance: 57CoCl2. The highest radioactivity of 57Co-bleomycin (cpm/mg protein) was observed in subcellular fractions containing mitochondria and lysosomes. After treatment of these fractions with hypertonic solutions it could be shown that enzymes of the mitochondrial matrix remained inside the vesicles under conditions of almost complete release of 57Co-bleomycin. Half of the lysosomal enzyme acid phosphatase was released too. From these experiments it is concluded that 57Co-bleomycin is preferentially localized in heavy secondary lysosomes which are more fragile than the lighter lysosomes in the cells.",
author = "A.W. Konings and J.J. Rasker",
year = "1978",
month = "1",
day = "1",
language = "English",
volume = "154",
pages = "63--70",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "1",

}

Subcellular localization of 57Co bleomycin in normal and tumor tissues. / Konings, A.W.; Rasker, J.J.

In: Strahlentherapie, Vol. 154, No. 1, 01.01.1978, p. 63-70.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Subcellular localization of 57Co bleomycin in normal and tumor tissues

AU - Konings, A.W.

AU - Rasker, J.J.

PY - 1978/1/1

Y1 - 1978/1/1

N2 - 57Co-bleomycin appears to be one of the best tumor detecting agents at the moment. The localization within the cells is not yet known. This preclinical investigation had the aim to study the subcellular distribution of 57Co-bleomycin in liver, spleen and tumors of rats and mice. Mice with transplanted lymphosarcoma and osteosarcoma were used and rats with transplanted rhabdomyosarcoma. The concentration of 57Co-bleomycin was 2 to 10 times higher in the tumors as compared to the (normal) liver. This accumulation property was not found with the control substance: 57CoCl2. The highest radioactivity of 57Co-bleomycin (cpm/mg protein) was observed in subcellular fractions containing mitochondria and lysosomes. After treatment of these fractions with hypertonic solutions it could be shown that enzymes of the mitochondrial matrix remained inside the vesicles under conditions of almost complete release of 57Co-bleomycin. Half of the lysosomal enzyme acid phosphatase was released too. From these experiments it is concluded that 57Co-bleomycin is preferentially localized in heavy secondary lysosomes which are more fragile than the lighter lysosomes in the cells.

AB - 57Co-bleomycin appears to be one of the best tumor detecting agents at the moment. The localization within the cells is not yet known. This preclinical investigation had the aim to study the subcellular distribution of 57Co-bleomycin in liver, spleen and tumors of rats and mice. Mice with transplanted lymphosarcoma and osteosarcoma were used and rats with transplanted rhabdomyosarcoma. The concentration of 57Co-bleomycin was 2 to 10 times higher in the tumors as compared to the (normal) liver. This accumulation property was not found with the control substance: 57CoCl2. The highest radioactivity of 57Co-bleomycin (cpm/mg protein) was observed in subcellular fractions containing mitochondria and lysosomes. After treatment of these fractions with hypertonic solutions it could be shown that enzymes of the mitochondrial matrix remained inside the vesicles under conditions of almost complete release of 57Co-bleomycin. Half of the lysosomal enzyme acid phosphatase was released too. From these experiments it is concluded that 57Co-bleomycin is preferentially localized in heavy secondary lysosomes which are more fragile than the lighter lysosomes in the cells.

UR - http://www.scopus.com/inward/record.url?scp=0017904239&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 63

EP - 70

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 1

ER -